Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.45 |
| ▸ | BCL2 | P10415 | 16/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058368 | 0.87 | BCL2L1 (0.51) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL14981030 | 0.84 | BCL2L1 (0.62) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL15513884 | 0.84 | BCL2L1 (0.62) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL10058364 | 0.83 | BCL2L1 (0.55) | BCL2L1BCL2 | |
| SCHEMBL10058370 | 0.78 | BCL2L1 (0.74) | BCL2L1BCL2 | |
| SCHEMBL19491759 | 0.75 | BCL2L1 (0.52) | BCL2L1BCL2MCL1BCL2L2NR3C1 | |
| SCHEMBL22879234 | 0.75 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL554588 | 0.74 | BCL2L1 (0.63) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL29658228 | 0.74 | BCL2L1 (0.63) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL554587 | 0.74 | BCL2L1 (0.63) | BCL2L1BCL2MCL1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | BCL2L1 5/4885BCL2 2/4885MCL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.